by uimmodulon_admin | 9th October 2018 | archive
Immodulon, the immuno-oncology company, is pleased to announce that Maikel Dijkstal will be joining the Immodulon Core Management Team as CMC Programme Manager with immediate effect. Based in The Netherlands, Maikel has spent much of his working career in...
by uimmodulon_admin | 1st October 2018 | archive
Immodulon, the immuno-oncology company, announces that their IMM-101-015 Phase II clinical trial has commenced. The open-label clinical study will assess the safety and efficacy of the combination of IMM-101 with Nivolumab, an immune checkpoint inhibitor, in 26...
by uimmodulon_admin | 18th July 2018 | archive
Immodulon, the immuno-oncology company, is pleased to announce that Dr Kevin Bilyard, who served as CEO of Immodulon from 2008 to 2016 and more recently been an advisor to the company’s Board of Directors, has accepted a position on the Immodulon Board. His...
by uimmodulon_admin | 2nd July 2018 | archive
Immodulon, the immuno-oncology company, today announces the appointment of Dr Jaap Kampinga, current Chief Scientific Officer (CSO), as Chief Executive Officer (CEO) effective from 1st July 2018. Dr Kampinga is a medical doctor and immunologist and has considerable...
by uimmodulon_admin | 19th February 2018 | archive
Immodulon, the immuno-oncology company, is pleased to announce the appointment of Dr Jerome Zeldis to the Immodulon Board who has also been offered the position of Chairman of the Scientific Advisory Board. Jerry joins the company from Celgene where he held the...
by uimmodulon_admin | 8th January 2018 | archive
Immodulon, the immuno-oncology company, is pleased to announce the appointment of Dr Jaap Kampinga as its Chief Scientific Officer. He will work closely with COO Graham Burton and the Immodulon Board to realise the company’s potential as leaders in cancer...
by uimmodulon_admin | 2nd October 2017 | archive
In IMAGE-1, a phase II proof-of-concept study recruiting 110 patients with locally advanced or metastatic pancreatic cancer, patients were randomized to receive IMM‑101 + gemcitabine or gemcitabine alone. This study was designed to provide indicative rather than...
by uimmodulon_admin | 2nd October 2017 | archive
Immodulon, the immuno-oncology company, is pleased to announce the appointment of Andy Clarke as its Non- Executive Chairman. He will be joined by Dr. Graham Burton as Chief Operating Officer. Andy has over 25 years’ experience of driving performance improvements in...
by uimmodulon_admin | 10th May 2017 | archive
Immodulon attended the 15th International Congress on Targeted Anticancer Therapies (TAT), which took place from the 6th- 8th March in Paris. TAT congresses are annual meetings on new molecular targets and innovative cancer therapeutics in the early phases of clinical...
by uimmodulon_admin | 2nd May 2017 | archive
The Office of Naval Research, which is part of the US Department of Defence, has awarded a grant of up to two years of support to Professor Stefan Reber (Laboratory for Molecular Psychosomatics, University of Ulm, Germany) for his work on the promotion of stress...